Abstract:Abstract Trabeculectomy remains the ‘gold standard’ intraocular pressure (IOP)-lowering procedure for moderate-to-severe glaucoma; however, this approach is associated with the need for substantial post-operative management. Micro-invasive glaucoma surgery (MIGS) procedures aim to reduce the need for intra- and post-operative management and provide a less invasive means of lowering IOP. Generally, MIGS procedures are associated with only modest reductions in IOP and are targeted at patients with mild-to-moderate glaucoma, highlighting an unmet need for a less invasive treatment of advanced and refractory glaucoma. The PRESERFLO® MicroShunt (formerly known as InnFocus MicroShunt) is an 8.5 mm-long (outer diameter 350 μm; internal lumen diameter 70 μm) glaucoma drainage device made from a highly biocompatible, bioinert material called poly (styrene- block -isobutylene- block -styrene), or SIBS. The lumen size is sufficiently small that at normal aqueous flow hypotony is avoided, but large enough to avoid being blocked by sloughed cells or pigment. The MicroShunt achieves the desired pressure range in the eye by draining aqueous humor from the anterior chamber to a bleb formed under the conjunctiva and Tenon’s capsule. The device is implanted ab externo with intraoperative Mitomycin C via a minimally invasive (relative to incisional surgery) surgical procedure, enabling precise control of placement without the need for gonioscopy, suture tension control, or suture lysis. The implantation procedure can be performed in combination with cataract surgery or as a standalone procedure. The MicroShunt received Conformité Européenne (CE) marking in 2012 and is intended for the reduction of IOP in eyes of patients with primary open-angle glaucoma in which IOP remains uncontrolled while on maximum tolerated medical therapy and/or in which glaucoma progression warrants surgery. Three clinical studies assessing the long-term safety and efficacy of the MicroShunt have been completed; a Phase 3 multicenter, randomized clinical study comparing the MicroShunt to primary trabeculectomy is underway. In preliminary studies, the MicroShunt effectively reduced IOP and use of glaucoma medications up to 3 years after implantation, with an acceptable safety profile. This article summarizes current literature on the unique properties of the MicroShunt, the preliminary efficacy and safety findings, and discusses its potential use as an alternative to trabeculectomy for glaucoma surgery.

Recurrent exposure of Preserflo Microshunt implant

Combined surgery and Preserflo coating with conjunctival graft autologous in acute pseudo‐exfoliative glaucoma

Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients

Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-block-styrene) surgical device for the treatment of primary open-angle glaucoma: a review

Ex-press glaucoma shunt with adjunctive amniotic membrane and mitomycin C for post-traumatic glaucoma

Postoperative Outcomes of PreserFlo MicroShunt in Patients with Exfoliation Glaucoma

PreserFlo MicroShunt versus trabeculectomy: an updated meta-analysis and systematic review

Evolution of the morphology of filtering blebs through anterior segment OCT , one, three and six months after Preserflo Microshunt implant and its correlation with intraocular pressure

Midterm Survival Results of Preserflo® in a Real-world Setting: A Retrospective 2-year Analysis

In vivo evaluation of a nanotechnology-based microshunt for filtering glaucoma surgery

Silicone Tube Miniature Drainage Device Implanted under Scleral Flap for the Surgical Treatment of Glaucoma.

One-Year Outcomes of Preserflo Microshunt for Primary Open Angle Glaucoma: A Systematic Review and Meta-Analysis

Comparing the safety and efficacy of Preserflo Microshunt implantation and trabeculectomy for glaucoma: A systematic review and meta‐analysis

Minimally invasive bleb surgery versus minimally invasive glaucoma surgery: a 12-month retrospective study

Wirksamkeit, Einflussfaktoren und Sicherheit des Preserflo MicroshuntEfficacy, Confounders and Safety of the Preserflo Microshunt

The “Pocket” Technique: A Novel Surgical Technique for Repair of Glaucoma Drainage Device Tube Exposure

Transient hyphema associated with PRESERFLO® MicroShunt surgery using a double-step knife in patients with glaucoma

Matched case–control comparison of surgical success after XEN45 Gel Stent and PRESERFLO MicroShunt implantation in a Caucasian population

Preserflo MicroShunt versus Trabeculectomy: Efficacy and Surgical Success within a Heterogenous Patient Cohort

Surgical Outcomes in Uveitic Glaucoma: Long-Term Evaluation of Trabeculectomy, Non-Penetrating Deep Sclerectomy, Ex-PRESS Shunt and Ahmed Glaucoma Valve. A 3-Year Follow-Up Study

A Schlemm’s canal scaffold for the treatment of elevated IOP